Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2019) Pachychoroid disease. Eye (Lond) 33:14–33. https://doi.org/10.1038/s41433-018-0158-4
Yanagi Y (2020) Pachychoroid disease: a new perspective on exudative maculopathy. Jpn J Ophthalmol 64:323–337. https://doi.org/10.1007/s10384-020-00740-5
Pang CE, Freund KB (2015) Pachychoroid neovasculopathy. Retina 35:1–9. https://doi.org/10.1097/IAE.0000000000000331
Article CAS PubMed Google Scholar
Chan WM, Lai TYY, Lai RYK, Tang EWH, Liu DTL, Lam DSC (2008) Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 28:85–93. https://doi.org/10.1097/IAE.0b013e318156777f
Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M (2015) One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 122:555–561. https://doi.org/10.1016/j.ophtha.2014.09.034
Haga F, Maruko R, Sato C, Kataoka K, Ito Y, Terasaki H (2017) Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: a 3-year follow-up study. PLOS One 12:e0181479. https://doi.org/10.1371/journal.pone.0181479
Article CAS PubMed PubMed Central Google Scholar
Lai TYY, Chan WM, Li H, Lai RKL, Liu DTL, Lam DSC (2006) Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 90:869–874. https://doi.org/10.1136/bjo.2006.090282
Article CAS PubMed PubMed Central Google Scholar
Oiwa K, Kataoka K, Maruko R, Ueno S, Ito Y, Terasaki H (2017) Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinograms. Jpn J Ophthalmol 61:260–266. https://doi.org/10.1007/s10384-017-0498-9
Guo J, Tang W, Xu S, Liu W, Xu G (2021) OCTA evaluation of treatment-naïve flat irregular PED (FIPED)-associated CNV in chronic central serous chorioretinopathy before and after half-dose PDT. Eye (Lond) 35:2871–2878. https://doi.org/10.1038/s41433-020-01345-5
Article CAS PubMed Google Scholar
Hikichi T, Kubo N, Yamauchi M (2021) One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy. Eye (Lond) 35:3367–3375. https://doi.org/10.1038/s41433-021-01418-z
Article CAS PubMed Google Scholar
Kitajima Y, Maruyama-Inoue M, Ito A, Sato S, Inoue T, Yamane S, Kadonosono K (2020) One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol 258:1279–1285. https://doi.org/10.1007/s00417-020-04661-4
Article CAS PubMed Google Scholar
Matsumoto H, Hiroe T, Morimoto M, Mimura K, Ito A, Akiyama H (2018) Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol 62:144–150. https://doi.org/10.1007/s10384-018-0562-0
Article CAS PubMed Google Scholar
Matsumoto H, Mukai R, Kikuchi Y, Morimoto M, Akiyama H (2020) One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn J Ophthalmol 64:203–209. https://doi.org/10.1007/s10384-020-00722-7
Article CAS PubMed Google Scholar
Miki A, Kusuhara S, Otsuji T, Kawashima Y, Miki K, Imai H, Nakamura M, Tsujikawa A (2021) Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PloS One 16:e0248760. https://doi.org/10.1371/journal.pone.0248760
Article CAS PubMed PubMed Central Google Scholar
Tanaka K, Mori R, Wakatsuki Y, Onoe H, Kawamura A, Nakashizuka H (2021) Two-thirds dose photodynamic therapy for pachychoroid neovasculopathy. J Clin Med 10:2168. https://doi.org/10.3390/jcm10102168
Article PubMed PubMed Central Google Scholar
Smretschnig E, Hagen S, Glittenberg C, Ristl R, Krebs I, Binder S, Ansari-Shahrezaei S (2016) Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. Eye (Lond) 30:805–811
Article CAS PubMed Google Scholar
Dansingani KK, Balaratnasingam C, Klufas MA, Sarraf D, Freund KB (2015) Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol 160:1243-1254e.2. https://doi.org/10.1016/j.ajo.2015.08.028
Fung AT, Yannuzzi LA, Freund KB (2012) Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 32:1829–1837. https://doi.org/10.1097/IAE.0b013e3182680a66
Terao N, Koizumi H, Kojima K et al (2018) Association of upregulated angiogenic cytokines with choroidal abnormalities in chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci 59:5924–5931. https://doi.org/10.1167/iovs.18-25517
Article CAS PubMed Google Scholar
Guo J, Tang W, Liu W, Chang Q, Xu G (2021) Clinical features of flat irregular pigment epithelial detachment associated with choroidal neovascularization in chronic central serous chorioretinopathy. Retina 41:199–207. https://doi.org/10.1097/IAE.0000000000002791
Article CAS PubMed Google Scholar
Demirel S, Yanık Ö, Özcan G, Batıoğlu F, Özmert E (2021) A comparative study on the choroidal vascularity index and the determination of cut-off values in the pachychoroid spectrum diseases. Jpn J Ophthalmol 65:482–491. https://doi.org/10.1007/s10384-021-00829-5
Article CAS PubMed Google Scholar
Wu JS, Chen SN (2019) Optical coherence tomography angiography for diagnosis of choroidal neovascularization in chronic central serous chorioretinopathy after photodynamic therapy. Sci Rep 9:9040. https://doi.org/10.1038/s41598-019-45080-8
Article CAS PubMed PubMed Central Google Scholar
Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S (2014) Photodynamic therapy for central serous chorioretinopathy. Eye (Lond) 28:944–957. https://doi.org/10.1038/eye.2014.134
Article CAS PubMed Google Scholar
Turkcuoglu P, Ilhan N, Kurt J, Aydemir O, Celiker U (2009) The protective role of Visudyne eyeglass against VEGF synthesis after photodynamic therapy with verteporfin. Acta Ophthalmol 87:871–874. https://doi.org/10.1111/j.1755-3768.2008.01368.x
Article CAS PubMed Google Scholar
Colucciello M (2006) Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Retina 26:239–242
Chen YC, Chen SN (2020) Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy. Br J Ophthalmol 104:1561–1566. https://doi.org/10.1136/bjophthalmol-2019-315302
Hu YC, Chen YL, Chen YC, Chen SN (2021) 3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization. Sci Rep 11:13286. https://doi.org/10.1038/s41598-021-92693-z
留言 (0)